

RIVFLOZA - (EQ 80MG BASE/0.5ML, EQ 128MG BASE/0.8ML, EQ 160MG BASE/ML ; Solution)

Generic Name	NEDOSIRAN SODIUM	Innovator	Novo Nordisk
Dosage	EQ 80MG BASE/0.5ML, EQ 128MG BASE/0.8ML, EQ 160MG BASE/ML ; Solution	Branded US Sales	Less Than \$1000 mn
Probable FTF	None	Known Para IV Filers	None
Other ANDA developers	None	Tentative Approvals	None
Final Approvals	None	Generic Launches	None
Indication	RIVFLOZA is an LDHA-directed small interfering RNA indicated to lower urinary oxalate levels in children 9 years of age and older and adults with primary hyperoxaluria type 1 (PH1) and relatively preserved kidney function, e.g., eGFR ? 30 mL/min/1.73 m2.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.